The minicolumnopathy of autism: A link between migraine and gastrointestinal symptoms

Medical Hypotheses

Volumn 70, Issue 1, 2008, Pages 73-80

  Casanova, Manuel F ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; SEROTONIN; SUMATRIPTAN;

ABDOMINAL DISEASE; ABDOMINAL MIGRAINE; ANAMNESIS; ARTICLE; AUTISM; AUTOPSY; BRAIN CORTEX; DIETARY INTAKE; FOOD ALLERGY; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; INFLAMMATION; MIGRAINE; MINICOLUMNOPATHY; NERVE CELL EXCITABILITY; PRIORITY JOURNAL; SENSORY STIMULATION; SEROTONIN RELEASE;

ABDOMEN; AUTISTIC DISORDER; AUTOPSY; CEREBRAL CORTEX; GASTROINTESTINAL DISEASES; HUMANS; MIGRAINE DISORDERS; SEROTONIN;

EID: 36348987634     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.04.025     Document Type: Article

References (91)

1. Lane R., and Davies P. Migraine (2006), Taylor & Francis, New York (NY)
2. Rice C. Prevalence of Autism Spectrum Disorders: Autism and Developmental Disabilities monitoring network, six sites, United States, 2000. Morbidity and Mortality Weekly Report 56 SS01 (2007) 1-11
3. Bailey A., Bolton P., Butler L., Le Couteur A., Murphy M., Scott S., et al. Prevalence of the fragile X anomaly amongst autistic twins and singletons. J Child Psychol Psychiatr 34 5 (1993) 673-688
4. Piven J., Gayle J., Landa R., Wzorek M., and Folstein S. The prevalence of fragile X in a sample of autistic individuals diagnosed using a standardized interview. J Am Acad Child Adolesc Psychiatr 30 5 (1991) 825-830
5. Kent L., Evans J., Paul M., and Sharp M. Comorbidity of autistic spectrum disorders in children with Down syndrome. Dev Med Child Neurol 41 3 (1999) 153-158
6. Moore S.J., Turnpenny P., Quinn A., Glover S., Lloyd D.J., Montgomery T., et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 37 7 (2000) 489-497
7. Bauman M., and Kemper T. The neurobiology of autism. 2nd ed. (2005), The Johns Hopkins University Press, Baltimore (MD)
8. Casanova M.F., Buxhoeveden D., Switala A., and Roy E. Minicolumnar pathology in autism. Neurology 58 (2002) 428-432
9. Casanova M.F., van Kooten I.A.J., Switala A.E., van Engeland H., Heinsen H., Steinbusch H.W.M., et al. Minicolumnar abnormalities in autism. Acta Neuropathol 112 3 (2006) 287-303
10. Sullivan R. Hunches on some biological factors of autism. J Autism Child Schiz 5 2 (1975) 177-186
11. Piven J., Arndt S., Bailey J., Havercamp S., Andreasen N.C., and Palmer P. An MRI study of brain size in autism. Am J Psychiatr 152 8 (1995) 1145-1149
12. Stromland K., Nordin V., Miller M., Akerstrom B., and Gillberg C. Autism in thalidomide embryopathy: a population study. Dev Med Child Neurol 36 4 (1994) 351-356
13. Silverman W.A. The schizophrenic career of a "Monster Drug". Pediatrics 110 2 (2002) 404-406
14. Casanova M.F., Buxhoeveden D., and Gomez J. Disruption in the inhibitory architecture of the cell minicolumn: implications for autisim. Neuroscientist 9 6 (2003) 496-507
15. Rakic P. Specification of cerebral cortical areas. Science 241 4862 (1988) 170-176
16. Chambers D., and Fishell G. Functional genomics of early cortex patterning. Genome Biol 7 1 (2006) 202
17. Favorov O.V., and Diamond M.E. Demonstration of discrete place-defined columns - segregates - in the cat SI. J Comp Neurol 298 1 (1990) 97-112
18. Favorov O.V., and Kelly D.G. Minicolumnar organization within somatosensory cortical segregates: I. Development of afferent connections. Cereb Cortex 4 4 (1994) 408-427
19. Mountcastle V.B. The columnar organization of the neocortex. Brain 120 4 (1997) 701-722
20. Tommerdahl M., Taman V., Cascio C.J., Baranek G.T., and Whitsel B.L. Vibrotactile adaptation fails to enhance spatial localization in adults with autism. Brain Res (2007) [Epub ahead of print]
21. Casanova M.F., Van Kooten I., Switala A.E., van Engeland H., Heinsen H., Steinbusch H.W.M., et al. Abnormalities of cortical minicolumnar organization in the prefrontal lobes of autistic patients. Clin Neurosci Res 6 3-4 (2006) 127-133
22. Blue M.E., and Johnston M.V. The ontogeny of glutamate receptors in rat barrel field cortex. Dev Brain Res 84 1 (1995) 11
23. Xu Y., Sari Y., and Zhou F.C. Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development. Dev Brain Res 150 2 (2004) 151
24. Shutoh F., Hamada S., Shibata M., Narita M., Shiga T., Azmitia E.C., et al. Long term depletion of serotonin leads to selective changes in glutamate receptor subunits. Neurosci Res 38 4 (2000) 365
25. Jobe P.C., and Browning R.A. The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Beh 7 4 (2005) 602
26. Smolders I. Differential glutamatergic modulation of monoamine release in the limbic lobe by selective anticonvulsant ionotropic and metabotropic glutamate receptor ligands. Verh K Acad Geneeskd Belg 67 5-6 (2005) 371-398
27. Gustafsson L. Comment on "disruption in the inhibitory architecture of the cell minicolumn: Implications for autism". Neuroscientist 10 3 (2004) 189-191
28. Fossier P., Blanchard B., Ducrocq C., Leprince C., Tauc L., Baux G., et al. Nitric oxide transforms serotonin into an inactive form and this affects neuromodulation. Neuroscience 93 2 (1999) 597
29. Liese E., Thavaradhara K., Durham N.R., and Turner B.E. Serotonin and nitric oxide regulate metamorphis in the marine snail Ilyanassa obsolete. Am Zool 41 2 (2001) 258-267
30. Powrozek T.A., and Zhou F.C. Effects of prenatal alcohol exposure on the development of the vibrissal somatosensory cortical barrel network. Dev Brain Res 155 2 (2005) 135
31. Persico A.M., Mengual E., Moessner R., Hall S.F., Revay R.S., Ichiro S., et al. Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine release. J Neurosci 21 17 (2001) 6862-6873
32. Janusonis S., Gluncic V., and Rakic P. Early serotonergic projections to cajal-retzius cells: Relevance for cortical development. J Neurosci 24 7 (2004) 1652-1659
33. Louderback K., Glass C.S., Shamalla-Hannah L., Erickson S.L., and Land P.W. Subbarrel patterns of thalamocortical innervation in rat somatosensory cortical barrels: organization and postnatal development. J Comp Neurol 497 1 (2006) 32-41
34. Chugani D., Muzik O., Behen M., Rothermel R., Janisse J.J., Lee J., et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 45 3 (1999) 287-295
35. Anderson G., Freedman D.X., Cohen D.J., Volkmar F.R., Hoder E.L., McPhedran P., et al. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatr 28 6 (1987) 885-900
36. Anderson G., Horne W.C., Chatterjee D., and Cohen D.J. The hyperserotonemia of autism. Ann N Y Acad Sci 600 (1990) 331-340
37. Cook E.H., Leventhal B.L., and Freedman D.X. Free serotonin in plasma: Autistic children and their first-degree relatives. Biol Psychiatr 24 4 (1988) 488
38. Hoshino Y., Yamamoto T., Kaneko M., Tachibana R., Watanabe M., Ono Y., et al. Blood serotonin and free tryptophan concentration in autistic children. Neuropsychobiology 11 1 (1984) 22-27
39. Schain R.F., and Freedman D.X. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 58 (1961) 315-320
40. McBride P., Anderson G.M., Hertzig M.E., Snow M.E., Thompson S.M., Khait V.D., et al. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. J Am Acad Child Adolesc Psychiatr 37 7 (1998) 767-776
41. Piven J., Tsai G.C., Nehme E., Coyle J.T., Chase G.A., and Folstein S.E. Platelet serotonin, a possible marker for familial autism. J Autism Dev Disord 21 1 (1991) 51-59
42. Anderson G. Serotonin in autism. In: Bauman M., and Kemper T. (Eds). The neurobiology of autism (2005), Johns Hopkins University Press, Baltimore (MD) 303-318
43. Hollander E., Novotny S., Allen A., Aronowitz B., Cartwright C., and DeCaria C. The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorder. Neuropsychopharmacology 22 2 (2000) 163-167
44. Adham N., Bard J.A., Zgombick J.M., Durkin M.M., Kucharewicz S., Weinshank R.L., et al. Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology 36 4-5 (1997) 569-576
45. Gordon C., State R.C., Nelson J.E., Hamburger S.D., and Rapoport J.L. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatr 50 6 (1993) 441-447
46. McDougle C., Naylor S.T., Cohen D.J., Volkmar F.R., Heninger G.R., and Price L.H. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatr 53 11 (1998) 1001-1008
47. Mehlinger R., Scheftner W., and Poznanski E. Fluoxetine and autism. J Am Acad Child Adolesc Psychiatr 29 6 (1990) 985
48. Steingard R., Zimnitzky B., DeMaso D.R., Bauman M.L., and Bucci J.P. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 7 1 (1997) 9-15
49. McDougle C., Naylor S.T., Cohen D.J., Aghajanian G.K., Heninger G.R., and Price L.H. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatr 53 11 (1996) 993-1000
50. Chez M.G., Chang M., Krasne V., Coughlan C., Kominsky M., and Schwartz A. Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. Epilepsy Beh 8 1 (2006) 267
51. Chugani D. Serotonin in autism and pediatric epilepsies. Mental Retard Dev Disabil Res Rev 10 2 (2004) 112-116
52. Arulmozhi D., Veeranjaneyulu A., and Bodhankar S. Migraine: current therapeutic targets and future avenues. Curr Vasc Pharmacol 4 2 (2006) 117-128
53. Silberstein S. Preventive treatment of migraine. Rev Neurol Dis 2 4 (2005) 167-175
54. Olmez A., Kose G., and Turanli G. Cyclic vomiting with generalized epileptiform discharges responsive to topiramate therapy. Pediatr Neurol 35 5 (2006) 348
55. Tan V., Sahami A.R., Peebles R., and Shaw R.J. Abdominal migraine and treatment with intravenous valproic acid. Psychosomatics 47 4 (2006) 353-355
56. Welch K. Concepts of migraine headache pathogenesis: insights into mechanisms of chronicity and new drug targets. Neurol Sci 24 Suppl. 2 (2003) S149-S153
57. Lane R. Migraine and epilepsy. Megrim 4 (1991) 8-12
58. Pietrobon D., and Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 4 5 (2003) 386-398
59. Ferrari M., Odink J., Bos K.D., Malessy M.J., and Bruyn G.W. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 40 10 (1990) 1582-1586
60. Mauskop A., and Altura B. Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci 5 1 (1998) 24-27
61. Grandin T. A personal perspective of Autism. In: Volkmar F., et al. (Ed). Handbook of autism and pervasive developmental disorders (2005), Wiley, New Jersey 1276-1286
62. Schreibman L. The science and fiction of autism (2005), Harvard University Press, Cambridge (MA)
63. Kaplan M., Edelson S., and Seip J. Behavioral changes in autistic individuals as a result of wearing ambient transitional prism lenses. Child Psychiatr Hum Dev 29 1 (1998) 65-76
64. Edelson S. Scotopic sensitivity syndrome and the Irlen Lens System, ; 2007 [cited].
65. Wilkins A. Reading through colour: how coloured filters can reduce reading difficulty, eye strain, and headaches (2003), Wiley, Sussez, England
66. Buie T. Gastrointestinal issues encountered in autism. In: Bauman M., and Kemper T. (Eds). The neurobiology of autism (2005), Johns Hopkins University Press, Baltimore, MD 103-117
67. Fombonne E., and Chakrabarti S. No evidence for a new variant of Measles-Mumps-Rubella-induced autism. Pediatrics 108 4 (2001) e58
68. Wakefield A.J., Murch S.H., Anthony A., Linnell J., Casson D.M., Malik M., et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. The Lancet 351 9103 (1998) 637
69. Murch S.H., Anthony A., Casson D.H., Malik M., Berelowitz M., Dhillon A.P., et al. Retraction of an interpretation. The Lancet 363 9411 (2004) 750
70. Sabra A., Bellanti J., and Colon A. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 352 9123 (1998) 234-235
71. Kokkonen J., and Karttunen T. Lymphonodular hyperplasia on the mucosa of the lower gastrointestinal tract in children: an indication of enhanced immune response?. J Pediatr Gastroenterol Nutr 34 1 (2002) 42-46
72. Knivsberg A., Reichelt K.L., Nodland M., and Hoien T. Autisitic syndromes and diet: a follow-up study. Scand J Edu Res 39 (1995) 223-236
73. Lucarelli S., Frediani T., Zingoni A.M., Ferruzzi F., Giardini O., Quintieri F., et al. Food allergy and infantile autism. Panminerva Med 37 3 (1995) 137-141
74. Casanova M., Buxhoeveden D., and Brown C. Clinical and macroscopic correlates of minicolumnar pathology in autism. J Child Neurol 17 9 (2002) 692-695
75. Casanova M., and Switala A.E. Minicolumnar morphometry: Computerized image analysis. In: Casanova M.F. (Ed). Neocortical modularity and the cell minicolumns (2005), Nova Science Publishers, New York (NY) 161-180
76. Vargas D., Nascimbene C., Krishnan C., Zimmerman A.W., and Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57 1 (2005) 67-81
77. Cullen K., and Macdonald W. The periodic syndrome: its nature and prevalence. Med J Aust 50 2 (1963) 167-173
78. Abu-Arafeh I., and Russell G. Prevalence and clinical features of abdominal migraine compared with those of migraine headache. Arch Dis Child 72 5 (1995) 413-417
79. Davidoff R. Migraine: Manifestatons, pathogenesis, and management. Contemporary neurology series (2002), Oxford University Press, Oxford, England
80. Sacks O. Migraine (1985), University of California Press, Berkley (CA)
81. Symon D. Equivalents, variants, and precursors of migraine. In: Guidetti V., et al. (Ed). Headache and migraine in childhood and adolescence (2002), Martin Dunlitz, LTD, London 215-227
82. Egger J., Carter C.M., Wilson J., Turner M.W., and Soothill J.F. Is migraine food allergy? A double-blind controlled trial of oligoantigenic diet treatment. Lancet 2 8355 (1983) 865-869
83. Isler H., and Rose F. Historical Background. In: Olesen J., Tfelt-Hansen P., and Welcj K. (Eds). The headaches (2000), Lippincoat, Williams and Wilkins, Philadelphia (PA) 1-7
84. Rose F. European neurology from its beginnings until the 15th century: an overview. J Hist Neurosci 2 1 (1993) 21-44
85. Lauritzen M. Pathophysiology of the migraine aura: The spreading depression theory. Brain 117 1 (1994) 199-210
86. Sanchez-del-Rio M., and Reuter U. Migraine aura: new information on underlying mechanisms. Curr Opin Neurol 17 3 (2004) 289-293
87. Chapman L., Ramos A.O., Goodell H., Silverman G., and Wolff H.G. A humoral agent implicated in vascular headache of the migraine type. Arch Neurol 3 (1960) 223-229
88. Kraig R.P., Dong L.M., Thisted R., and Jaeger C.B. Spreading depression increases immunohistochemical staining of glial fibrillary acidic protein. J Neurosci 11 7 (1991) 2187-2198
89. Spierings E. Inflammation in migraine pathogenesis: when, where, and how. In: Spierings E., and Sanchez-del-Rio M. (Eds). Migraine:A neuroinflammatory disease? (2002), Birkhauser Verlag, Bassel 1-20
90. Mohammad Y, Kothari R, Hughes G, Nikrumah M, Fischell S, Fischell R, Schweiger J, Ruppel P. Transcranial magnetic stimulation (TMS) relieves migraine headache. In: 48th annual scientific meeting of the American Headache Society (AHS), Los Angeles; 2006.
91. Geller E., Ritvo E.R., Freeman B.J., and Yuwiler A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. New Eng J Med 307 3 (1982) 165-169